NOSIUM AB (publ) ("NOSIUM" eller "Bolaget") meddelar att Medicortex Finland Oyj ("Medicortex"), det finska medicinteknikbolag som NOSIUM förvärvar genom det Share Purchase Agreement som signerades den 17 november 2025, har beviljats ett europeiskt patent av European Patent Office (EPO).

Det europeiska patentet "A method for diagnosis of traumatic brain injury" (EP4483187) beviljades av EPO den 3 december 2025. Patentet skyddar en metod för detektion och användning av specifika kolhydratkompositioner som biomarkörer för traumatiska hjärnskador (TBI). Dessa markörer kan detekteras i icke-invasiva prover av kroppsvätska såsom urin eller saliv.

Detta är Medicortex tionde patent och stärker bolagets redan starka patentportfölj inom TBI-diagnostik. Patentet bekräftar Medicortex unika approach med glycanbaserade biomarkörer och säkerställer fortsatt exklusivitet för bolagets produktutveckling.

"Detta är ytterligare ett bevis på styrkan i Medicortex teknologi och deras förmåga att skydda sina innovationer. Ett starkt patentskydd är avgörande för framgångsrik kommersialisering och skapar betydande värde för aktieägarna," säger Jesper Yrwing, VD för NOSIUM AB (publ).

Läs Medicortex kompletta pressmeddelande här:https://www.sttinfo.fi

Kort om Medicortex Finland Oyj

Medicortex Finland Oyj är ett finskt medicinteknikbolag som utvecklar icke-invasiva diagnostiska test för traumatiska hjärnskador. Bolaget har erhållit 8,4 miljoner EUR i finansiering, inklusive tre anslag från US Department of Defense, och har nu en stark patentportfölj med 10 patent. Mer information på medicortex.fi.

BIFOGAT PRESSMEDDELANDE FRÅN MEDICORTEX FINLAND OYJ:

A European patent granted for Medicortex

The European Patent Office (EPO) has granted a patent for Medicortex Finland Oyj, a biopharmaceutical company focusing on development of diagnostics and treatments for traumatic brain injury (TBI). The patent strengthens Medicortex's unique approach for detection of glycan-based indicators of brain trauma.

The European patent "A method for diagnosis of traumatic brain injury" (EP4483187) was granted by the EPO on 3 December 2025. The patent protects a method of detection and use of certain carbohydrate compositions as biomarkers of TBI. The markers can be detected in non-invasive samples of body fluid such as urine or saliva.

Medicortex has received another confirmation of its expertise in protecting innovative new technologies that the company has developed in-house by its experienced research team.

Dr. Adrian Harel, CEO of Medicortex says: "This is a great achievement - we are very pleased with the increase of our patent portfolio, company's intellectual property covering methods of using certain biomarkers for detection of concussion and TBI. Issuance of this patent is another important step in the development of a new strategy to help identify and treat TBI."

Medicortex's patent portfolio encompasses biomarkers and methods of TBI detection as well as drug candidates developed by the company for halting the progression of TBI. The comprehensive patent coverage secures exclusivity to develop the products, and the company's strategy is to actively seek new patentable innovations from its biomarker and drug development programs.

Forward-looking statements

Certain statements in this communication are forward-looking statements. They are based on the views of the company's management, as well as the understanding and assumptions of the company's management based on the information available at present, and due to this, they may be forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, which may result in that the company's actual future results, operations, achievements and performance of the sector may differ significantly from the expectations conveyed in these statements. Forward-looking statements are not a guarantee of the company's operational or financial performance in the future.

Keywords

diagnostics, patent, biomarker, concussion, TBI, brain injury

Contacts

Adrian Harel, CEOTel: +358 400 488 817Email: adrian.harel@medicortex.fi

About the company

Medicortex Finland Oyj is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on developing biomarker diagnostics to detect brain injury easily. The company has technology to capture biomarkers from urine and saliva and capability to develop an affordable diagnostic tool to detect biomarkers. Company's second goal is to develop new compounds to serve as drug candidates to halt progression of brain injury and reduce the secondary degeneration. Medicortex was founded by an experienced Neurobiologist Adrian Harel (PhD, MBA) and the company is based in Turku, Finland.

För ytterligare information vänligen kontakta

Jesper Yrwing, VD, jesper@nosium.com, tel. +46 70 860 60 07

Kort om NOSIUM

NOSIUMs investerar i entreprenörer. Våra investeringar återfinns i entreprenörsdrivna och visionsdrivna företag där vi kan bistå företaget med mer än kapital. Vi äger, förvaltar och förvärvar aktier i företag där vi tror på en långsiktigt god värdeutveckling. Mer information på nosium.com.

Bifogade filer

MEDICORTEX BEVILJAS EUROPEISKT PATENT – STÄRKER SKYDDET FÖR UNIK TBI-DIAGNOSTIK